Dual effects of constitutively active androgen receptor and fulllength androgen receptor for N-cadherin regulation in prostate cancer

Supplementary Materials
MATERIALS AND METHODS
Plasmids
To study the importance of DNA binding properties of AR variants for upregulation of N-cadherin, cysteine in position 576 was substituted to a tyrosine to yield to the AR-V7-C576Y mutant. This mutant was unable to bind DNA. Briefly, the mutation was introduced in AR-V7 sequence using the following polymerase chain reaction (PCR) primers: a HindIII site-linked primer containing the G2845A mutation 5′GCCTGATCTGTGGAGATGAAGCTTCTGGGTGTC ACTATGGAGCTCTCACAT ATGGAAGCTCAA3′ (NM_000044.3; nucleotides 2784-2853) as the forward primer and a BamHI site-linked primer 5′CAGTTATCTAGATCCGGTGGATCCCTTTCTTCAG GGTCTGGTCATTTTGAGATGCTTGCAATTGC 3′ (FJ235916.1; nucleotides 2230-2272 in italics; U57607.1; nucleotides 1387-1409 underlined) as the reverse primer. pE-AR-V7-C576Y and pEGFP-AR-V7-C576Y were constructed from previously described pE-AR-V7 and pEGFP-AR-V7 respectively, by replacing the HindIII/BamHI fragment with` the C576Y mutant sequence using In fusion ® HD Cloning Kit (Clontech). For luciferase assay, the CDH2 promoter (NC_000018.10, position 28177782-28177023) and intron 1 CDH2 genomic sequence (NC_000018.10, position 28157248-28156350) containing 13 AREs were inserted into pGL4.14 vector (Promega) to yield to the pARE_CDH2luc plasmid. CDH2 promoter and intron 1_CDH2_ARE sequences were amplified from genomic DNA of LNCaP cells using the following primers: the forward primer incorporating KpnI restriction site 5′TATTATGGTACCACGGAGCCGCGGCGGGAG AGACCGC3′ and the reverse primer incorporating Hind III restriction site 5′TATTATAAGCTTGGAGG CGGAG AGGGGCCGAGCGAAGA3′ for promoter; the forward primer with BamHI restriction site 5′TATTATGGATCCTATAAGCGTGTTGCAGTCTCTG CTG3′ and the reverse primer with SalI restriction site 5′TATTACGTCGACGGACAAAAATCTGGGTCAAAA TCTGGG3′ for ARE sequence. The amplicons were cloned by ligation into pGL4.14 vector between KpnI/ HindIII and BamHI/SalI for CDH2 promoter and ARE sequence respectively.
Transient transfection
LNCaP cells were transfected using JetPEI TM (Polyplus Transfection, Ozyme) according to the manufacturer's protocol. Briefly, 2.5x10 5 LNCaP cells were seeded in 6-wells plates and transfected three days later with 3 µg of pE-AR-V7 or pE-AR-V7-C576Y plasmid using 6 μL of JET-PEI (Polyplus Transfection, Ozyme). Cells were incubated during 4 days in complete medium supplemented with 10 nM dihydrotestosterone (DHT) and RNA was isolated using NucleoSpin ® RNA II assay (Macherey-Nagel).
Luciferase assay
LNCaP cells (1.5 × 10 4 /well) were plated in 96-wells plates for three days. Cells were then cotransfected with 75 ng of pE-AR-V7 or pE-AR-V7-C576Y, 150 ng of luciferase reporter plasmid pARE_ CDH2luc and 7.5 ng of Renilla luciferase plasmid as an internal control using 0.5 μL of JET-PEI/well. Twentyfour hours after transfection, medium was replaced with phenol red-free RPMI 1640 containing 5% charcoalstripped FBS (CSS) with 10 nM DHT. Firefly and Renilla luciferase activities were measured 72 h after transfection using Dual-Glo Luciferase Assay according to the manufacturer's protocol (Promega). 
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